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Purpose: To evaluate the performance of Charlson Comorbidity Index (CCI) calculated
using hospitalization and medication reimbursement databases in predicting mortality.
Patients and methods: Information on hospitalizations was obtained from the national
Care Register for Health Care (HILMO) and on medication reimbursements and entitlements
for special reimbursements for medications from the Social Insurance Institution for 77,440
men aged 56–71 years at baseline. The subjects were followed up for mortality via Statistics
Finland with 20,562 deaths during a 13-year follow-up.
Results: Compared to a CCI score of 0, the age-adjusted hazard ratio for all-cause mortality
associated with HILMO-based CCI scores of 1, 2 and 3 or more were 2.39 (95% CI 2.29–
2.49), 2.96 (95% CI 2.81–3.13) and 6.42 (95% CI 5.95–6.93) at 13 years. The C-statistic was
0.72 at 1, 0.68 at 5 and 0.66 at 13 years, with only minor improvement over age alone (0.10,
0.06 and 0.04 accordingly). Addition of medication data did not improve predictive abilities
and medication-based CCI performed poorly on its own.
Conclusion: The hospitalization-based CCI, as well as that based on both databases,
predicts relative mortality adequately, but its discriminative ability diminishes over time.
Conditions related to hospitalizations affect survival more than medications.
Keywords: mortality, comorbidity, follow-up studies, hospitalization/statistics and
numerical data, drug prescriptions/statistics and numerical data, confounding factors
Introduction
In medical research, the outcome of interest, such as survival is often inﬂuenced by
confounding and effect modiﬁcation due to comorbidities. Hence, adjustment for
comorbidities is often necessary. Analysis and data acquisition of multiple indivi-
dual comorbidities is generally ineffective, and a simple standardized score describ-
ing comorbidity burden is often preferable.
Several comorbidity indices based on various sources of information and dif-
ferent criteria have been developed for predicting various outcomes.1–4 When the
outcome of interest is mortality and information on diagnoses is available, the
Charlson Comorbidity Index (CCI) is most commonly used.
CCI is a weighted index, originally based on the impact of major diseases on
relative mortality of hospitalized patients during a 1-year follow-up.1 The original
CCI was based on data derived from medical records and covered a total of 19
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diseases graded by severity providing a score for predict-
ing the relative risk of death compared to a low-risk
population. It has been shown to predict both short- and
long-term mortality.1,5–9 After the introduction of the
index, several updates and modiﬁcations of the index
have been published to maintain and improve its
applicability.6–9 During the evolution of the index, the
number of included diseases and the score weighting
have varied.
The index has been validated in many countries for use
with administrative registries and its performance has been
compared to other diagnosis-based indices (eg, Elixhauser)
and pharmacy-based indices (eg, RxRisk-V and CDS).6–15
The Elixhauser index seems to perform best in mortality
prediction, with CCI a close second. However, the calcula-
tion of the Elixhauser index is more complicated.16
Most studies on CCI have utilized speciﬁc subpopula-
tions, eg, cohorts selected from hospitalized patients,
which ensures availability of health care data and hence
feasibility of calculating the index.12–14,17,18 This limits
the generalizability of the results to larger, less selective
populations, such as the general population, where undo-
cumented illnesses could reduce the predictive power of
the index. Nevertheless, reasonable validity of the index
has also been demonstrated in some population-based stu-
dies, but the performance of the comprehensive Finnish
administrative databases for such task has not been
evaluated.10,11
The aim of our population-based study is to assess the
performance of CCI based on the Finnish national Care
Register for Health Care (HILMO), which resembles the
widely utilized English Hospital Episode Statistics
(HES).19 We also evaluate the performance of medication
databases of the Social Insurance Institution of Finland
(SII) as an alternative data source for calculating CCI.
Additionally, we compare the performance of two pre-
viously proposed modiﬁcations of the index and evaluate
their predictive characteristics during long-term follow-up.
Materials And Methods
The study population consisted of the men in the Finnish
Prostate Cancer Screening Trial (FinRSPC), the largest
component of European Randomized Study of Screening
for Prostate Cancer (ERSPC). After exclusion of men with
a prevalent prostate cancer at entry, the Finnish trial
included at baseline 80,458 men born in 1929–1944 and
living in the Helsinki or Tampere metropolitan area. The
population was identiﬁed from the Finnish Population
Registry. Of them, 32,000 men were randomly assigned
to the screening arm and received an invitation to screen-
ing for prostate cancer. The remaining 48,458 men formed
the control arm and received no intervention.
The follow-up for the current study started on January
1st, 2000, and at that time, 46,630 men in the control arm
and 30,810 on the screening arm were alive. Follow-up
ended at death or on the common closing date of
December 31st, 2012.
We used two modiﬁcations of CCI to estimate comor-
bidity, those by Deyo and Quan. Deyo’s index, the most
commonly used adaptation, is largely similar to the original
CCI and merely reduces the number of conditions to 17 by
combining leukemia, lymphoma and other malignancies
into a single group (Supplementary material 1).6,16 One of
the most recent updates, the Quan’s adaptation, not only
reduced the number of diseases to 12 but also changed the
weighting of the score (Supplementary material 1).9
To calculate the CCI score, information on diseases was
obtained from three different registries for the period 1996–
1999. The score was calculated using the diagnosis data
provided by HILMO and SII registries separately and then
by using the pooled diagnostic data from both sources.
The nationwide Care Registry for Health Care covers in-
patient hospital episodes, day surgery and tertiary outpatient
visits.20 The primary diagnosis and an unlimited number of
secondary diagnoses have been recorded using the 10th
revision of the International Classiﬁcation of Diseases
(ICD-10) since 1996 for all public and private hospitals in
Finland.21 Besides appropriate diagnoses, area of residence,
admission and discharge dates, and hospital ID are recorded.
ICD-10 diagnoses were modiﬁed to achieve compat-
ibility with the CCI diagnoses using an algorithm
developed by Deyo, Sundarajan, Halfon and Quan
(Supplementary material 1).6,22,23
All permanent residents of Finland are eligible for reim-
bursements for the cost of medicines prescribed by a physician
or a dentist. The reimbursements are administered by SII, a
governmental organisation responsible for the comprehensive
health insurance system. SII has maintained a database on
reimbursements for prescription medicines since 1995 and
on entitlements for special reimbursement since 1968.24,25
The Finnish pharmacy database was searched for drugs
that list conditions used for calculating the CCI as an
indication.26 Only those medications were used for which
the indications of use were sufﬁciently unequivocal to
enable determination of the underlying medical condition.
Pylväläinen et al Dovepress
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A special entitlement for reimbursement is required for
certain expensive medications and some conditions entitle
patients to a higher rate of reimbursement. These entitle-
ments and reimbursements require a medical certiﬁcate
demonstrating that the diagnostic criteria are fulﬁlled.
The eligibility criteria of entitlements to special reimbur-
sements were checked accordingly for unanimously con-
clusive CCI compatible diseases.27
The entitlement and Anatomical Therapeutic Chemical
(ATC) codes of drugs allowing determination of the CCI
compatible diagnoses are listed in Supplementary material 1.
Compatible drugs were found for ﬁve (dementia, cerebrovas-
cular disease, chronic pulmonary disease, rheumatologic dis-
ease and diabetes without chronic conditions) and ﬁtting
entitlements for seven (dementia, congestive heart failure,
chronic pulmonary disease, rheumatologic disease, diseases
without chronic complications, moderate or severe renal dis-
ease and any malignancy) out of 17 conditions.
Information on deaths was obtained from the Causes of
Death Registry of the Statistics Finland covering all deaths
of Finnish residents.
The Harrell’s C-statistic or area under the curve
(AUC) was used as an indicator of discriminative abil-
ity. For interpretation, it has been suggested to consider
a C-statistic value of < 0.7 poor, 0.7–0.8 acceptable and
> 0.8 excellent.28 We calculated the C-statistic by using
logistic regression with death from any cause as the
dependent variable, and age and CCI score as indepen-
dent predictor variables. The Akaike’s Information
Criterion (AIC) was calculated to assess the relative
goodness of ﬁt and model simplicity. The hazard ratio
for death was estimated using Cox regression and sur-
vival time using the age-adjusted Kaplan–Meier method.
95% conﬁdence intervals (CI) and p-values were calcu-
lated to assess the statistical signiﬁcance of differences
between methods. P-values of less than 0.05 were
regarded as statistically signiﬁcant. All analyses were
performed with Stata version 15.1.
Results
The mean age of the study population at entry was 62.5
years (SD 4.6 years). The median follow-up time was 13
years. During the follow-up, there were 20,562 deaths
from all causes, with cumulative mortality of 26.6% at
13 years. Prevalence of diseases included in the Deyo’s
adaptation of CCI is listed in Supplementary material 2.
When CCI was calculated using the Deyo’s adaptation
based on HILMO alone, 11.0% of the study population
had a CCI score of 1 or more at baseline (Table 1). The
average CCI for the population with any comorbidity was
1.57. The age-adjusted Kaplan–Meier survival estimates
for men with CCI score 0 versus 3 or more were 99% vs
92% at 1 year, 96% vs 64% at 5 years and 87% vs 33% at
13 years (Figure 1). The survival probability decreased
monotonously with increasing CCI score.
Compared to the men with a CCI score of 0, the age-
adjusted hazard ratio (HR) for all-cause mortality asso-
ciated with a score of 1 was 2.39 (95% CI 2.29–2.49) at 13
years. For men with a score of 2, the HR was 2.96 (95%
CI 2.81–3.13) and those with a score of 3 or more 6.42
(95% CI 5.95–6.93) (Table 3).
With the method in question, C-statistic for predicting
mortality was 0.72 (95% CI 0.71–0.74) at 1 year, 0.68
(95% CI 0.68–0.69) at 5 and 0.66 (95% CI 0.65–0.66) at
13 years, with statistically signiﬁcant (P<0.001) but minor
incremental contribution over age alone (difference in C
statistic 0.10 at 1 year, 0.06 at 5 years and 0.04 at 13 years)
(Table 4). The weakening of discriminative ability over
time is depicted in Figure 2.
Compared to HILMO-based CCI, combining all three
registries to derive the Deyo’s adaptation of the CCI resulted
in higher comorbidity prevalence (25.2% vs 11.0%) (Table 1),
but slightly lower average CCI score among men with comor-
bidity (1.44 vs 1.51). Results for survival (Figure 1, Tables 2
and 4) and hazard ratios (Table 3) were similar. Using all three
registries provided statistically signiﬁcant, but marginal
improvement in the discriminative ability only at 13 years
Table 1 The Number Of Men By Deyo’s And Quan’s Adaptation Of The Charlson Comorbidity Index (CCI) Based On The Care
Registry For Health Care (HILMO) And Medication Data (SII) Separately And In Combination
Comorbidity
Score
SII-Based
Deyo’s CCI
SII-Based
Quan’s CCI
HILMO-Based
Deyo’s CCI
HILMO-Based
Quan’s CCI
HILMO- And SII-
Based Deyo’s CCI
HILMO- And SII-
Based Quan’s CCI
0 61,739 (79.7%) 68,381 (88.3%) 68,924 (89.0%) 72,947 (94.2%) 57,891 (74.8%) 65,887 (85.1%)
1 13,250 (17.11%) 7206 (9.3%) 5078 (6.6%) 1443 (1.9%) 13,697 (17.7%) 7225 (9.3%)
2 2107 (2.7%) 1512 (2.0%) 2565 (3.3%) 2570 (3.3%) 4121 (5.3%) 3256 (4.2%)
3+ 344 (0.44%) 341 (0.44%) 873 (1.1%) 480 (0.6%) 1731 (2.2%) 1072 (1.4%)
Dovepress Pylväläinen et al
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(C-statistic difference 0.005, P<0.001). Accordingly, AIC was
lowest at 13 years using all registries but lowest at 1 and 5
years when the HILMO data alone were used.
Using only the SII reimbursement and entitlement data
resulted in a CCI score >0 for 20.3% of the men (Table 1).
The scores were lower on average compared with the
Figure 1 Kaplan–Meier survival estimates for Deyo’s and Quan’s adaptation of the Charlson Comorbidity Index derived from the hospitalization (HILMO) and medication
(SII) data separately and in combination.
Pylväläinen et al Dovepress
submit your manuscript | www.dovepress.com
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HILMO data alone (average CCI 1.18 vs 1.57) and
showed weaker discriminative ability at each observation
point for both adaptations (Tables 3 and 4).
The Quan’s adaptation of the index yielded lower comor-
bidity prevalence and comorbidity scores with each data
source (Table 1). Similar, but less consistent, increase in
mortality and reduction in survival across the CCI scores
were seen as with Deyo’s adaptation. When only the hospi-
talization data were used, the difference in mortality at 13
years between men with CCI of 1 and 2 (HR 3.24, 95% CI
3.03–3.47 vs 3.04, 95% CI 2.88–3.20) was insigniﬁcant. The
C-statistics of each source was marginally but statistically
signiﬁcantly lower (P<0.02) for Quan’s than Deyo’s adapta-
tion (Table 4).
Figure 2 Time-Dependent C-Statistics Calculated Using Age And Combination Of Deyo’s Adaptation Of Charlson Comorbidity Index (CCI) Based On The Care Registry
For Health Care (HILMO) And Age As Independent Predictor Variables.
Table 2 The Survival Rates Of Men At 13 Years By Deyo’s And Quan’s Adaptation Of The Charlson Comorbidity Index (CCI) Based
On The Care Registry For Health Care (HILMO) And Medication Data (SII) Separately And In Combination
Comorbidity
Score
SII-Based
Deyo’s CCI
SII-Based
Quan’s CCI
HILMO-Based
Deyo’s CCI
HILMO-Based
Quan’s CCI
HILMO- And SII-
Based Deyo’s CCI
HILMO- And SII-
Based Quan’s CCI
0 47,666 (77.2%) 51,534 (75.4%) 53,006 (76.9%) 55,171 (75.6%) 45,659 (78.9%) 50,478 (76.6%)
1 8208 (62.0%) 4715 (65.4%) 2576 (50.7%) 567 (39.3%) 8737 (63.8%) 4743 (65.7%)
2 928 (44.0%) 544 (36.0%) 1125 (43.9%) 1055 (41.1%) 1990 (48.3%) 1382 (42.4%)
3+ 76 (22.1%) 85 (24.9%) 171 (19.6%) 85 (17.7%) 492 (28.4%) 275 (25.7%)
Table 3 Hazard Ratios (HR) Of Death With Their 95% Conﬁdence Intervals (In Parentheses) Of Two Derivations Of The Charlson
Comorbidity Index (CCI) Calculated From The Care Registry For Health Care (HILMO), Social Security Institution (SII) And Their
Combination
Comorbidity
Score
SII-Based
Deyo’s CCI
SII-Based
Quan’s CCI
HILMO-
Based Deyo’s
CCI
HILMO-
Based Quan’s
CCI
HILMO- And SII-
Based Deyo’s CCI
HILMO- And SII-
Based Quan’s CCI
0 1 1 1 1 1 1
1 1.71 (1.65 −1.76) 1.42 (1.36–1.48) 2.39 (2.29–2.49) 3.24 (3.03–3.47) 1.76 (1.70–1.82) 1.50 (1.44–1.56)
2 2.81 (2.64–2.98) 3.13 (2.93–3.34) 2.96 (2.81–3.13) 3.04 (2.88–3.20) 2.72 (2.59 −2.85) 2.92 (2.78–3.07)
3+ 5.21 (4.61–5.88) 4.40 (3.89–4.98) 6.42 (5.95–6.93) 7.03 (6.36–7.77) 5.05 (4.76–5.35) 5.02 (4.68–5.40)
Dovepress Pylväläinen et al
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Discussion
Our results indicate that the Charlson Comorbidity Index
calculated using hospitalization data (from the Finnish
national Care Register for Health Care, HILMO) alone or
combined with the medication databases of the Social
Insurance Institution of Finland (SII) performs in an
acceptable fashion in predicting 1-year mortality, but its
performance wanes over time. The incremental contribu-
tion of the index to discriminate men at higher risk of
death compared to age alone was minor and correspond-
ingly diminished with longer follow-up.
Compared to CCI based on HILMO data alone, the
additional data on prescription medications and entitle-
ments for special reimbursement increased the prevalence
of comorbidity without substantially improving the discri-
minative ability of the index. Usage of medication-based
data alone resulted in poorest discrimination. The predic-
tive properties of Quan’s adaptation of the CCI were found
to be slightly worse all-around than Deyo’s.
Whether using all registries or hospitalization data
alone, an acceptable level of discrimination was achieved
for 1-year mortality with both adaptations. When Deyo’s
adaptation was used, the C-statistic was 0.72 for HILMO
and all registries, whereas the C-statistic for Quan’s adap-
tation was 0.71 for both approaches accordingly. These
results are in line with previous studies on administrative
registries, which have reported C-statistic ranging 0.711 to
0.882 for 1-year mortality.9,10,12–14,29
The additional discriminative contribution of CCI over
age and gender was statistically signiﬁcant, but minor in
absolute terms, and diminished over time (0.10 for hospi-
talization data alone and all registries for 1-year mortality,
down to 0.04, respectively, for 13-year mortality). In pre-
vious studies, the reported incremental contribution of the
CCI to the discriminative capacity of the predictive model
over base model (which generally includes age and gender
but also other covariates) has ranged from 0.026 to
0.113.11–13,29 Similar reductions in discrimination at
extended follow-up have been reported earlier, but to our
knowledge, our study is the ﬁrst one to evaluate follow-up
extending beyond 10 years.10,11
When Deyo’s adaptation was used, the hazard ratios
during the entire 13-year follow-up for a CCI score of 1
(relative to zero) were 2.4 (95% CI 2.29–2.49) for hospi-
talization data and 1.7 (95% CI 1.65–1.76) for medication
data. In the original CCI, the weighting of 1 was assigned
for diseases with hazard ratio of 1.2–1.5 at 1 year, which is
comparable to our results with medication data.1 The hos-
pitalization data seem to capture more severe and
advanced conditions so that adequate discriminative ability
for predicting mortality can be achieved even with a low
comorbidity prevalence (11.0%). The addition of medica-
tion data increased the prevalence (25.2%) of comorbidity
without substantially improving the discriminative ability.
Similar results have been found in two previous studies by
Lu et al (2011) and Crooks et al (2015).11,13 The former
reported a higher prevalence of lesser comorbidities with a
pharmacy-based Rx-Risk-V index, whereas the prevalence
of more severe comorbidities was higher with a hospitali-
zation-based CCI. The latter found that though population-
based primary care data identiﬁed a higher prevalence of
comorbidity than secondary care, this did not result in
improved predictive performance of CCI. Such emphasis
on lesser conditions and limitation of use to only a few
diseases due to lack of speciﬁcity due to multiple indica-
tions may explain the poor performance of discriminative
ability of medication data.
To our knowledge, our study is the ﬁrst one to evaluate
the additional value of medication data over other methods
for calculating CCI. A previous study used medication data
as an additional source data for CCI calculation, but no
information on its additional contribution was reported.18
Our study had some limitations. It was limited to men
only. Also, as our population-based study utilized routi-
nely collected health care data, we share their quality-
related limitations, which reﬂect on the performance of
the index.
As some conditions included in CCI are managed
mainly in primary care and do not necessarily require in-
patient care, day surgery or tertiary outpatient visits, hos-
pitalization data seem to underestimate the prevalence of
minor comorbidities and emphasize more severe condi-
tions. The completeness and accuracy of the Care
Registry for Health Care has been reported to vary from
satisfactory to very good depending on the condition, with
poor recording of subsidiary diagnoses as a recognised
limitation.21 The accuracy of some CCI compatible dis-
eases (coronary heart disease, dementia, cerebrovascular
disease, cervical cancer, and heart failure) has been pre-
viously evaluated with sensitivity ranging 11% to 97% (eg,
11% for heart failure and 90–97% for stroke) and positive
predictive value (PPV) ranging from 73% to 97%.21,30–36
The validity of data has been shown to improve over time
and further improvement can be expected, as recording of
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hospitalization data was expanded to include primary
health care visits in 2011.20,36
The utility of medication reimbursement and special
entitlement data for calculating CCI was limited. Few
drugs had sufﬁciently speciﬁc indications to allow
unequivocal deﬁnition of the diagnosis (Supplementary
material 1). Most medications have a range of possible
indications, making it impossible to classify the use of
drugs to a single condition category of CCI. Also, dur-
ing 1996–1999, the number of diseases meriting special
entitlements was small (though it has since increased).37
Most conditions entitling for a special reimbursement
used in the study were introduced in 1999 (eg, dementia
drugs), just before the baseline of the study, and corre-
spondingly the end of the data collection period for
morbidity.
Few studies have estimated the validity of special
entitlement data of CCI compatible diseases. In the pre-
viously referenced study conducted by Mähönen et al
(2013), special entitlement data had better validity than
HILMO with sensitivity and PPV of 23% and 93% for
heart failure.30 The same study also estimated the validity
of pharmacy data producing sensitivity of 5.8% and PPV
of 28.6% for heart failure, but such drugs were left out of
our study for having too diverse indications. Another study
has estimated the validity of Alzheimer’s disease (AD)
entitlements (SII entitlement code 307) and found the
PPV to be 97.1% and sensitivity 63.5%.36 However,
since AD is only one of the causes of dementia and
reimbursement of dementia drugs did not start until
January 1999, this may not reﬂect the validity of our
method.
The large and representative study population and the
long follow-up were the major strengths of our study.
Access to comprehensive register data on hospital admis-
sions and medications, with deterministic record linkage,
allowed us to obtain comprehensive coverage of the data
for the study. Since the study was population-based, its
generalizability in Finland should be good, as the registries
used are nationwide. Also, complete follow-up for mortal-
ity was an advantage, minimising the risk of selection and
information bias.
Conclusions
According to our study, the CCI can be calculated using
the Finnish national hospitalization registry. And there-
fore, the CCI can be used to adjust for comorbidity-
related mortality inexpensively and relatively
effortlessly in the Finnish population by utilizing routi-
nely collected health care registries. In accordance with
previous studies, the additional predictive value over
age alone was modest and diminished signiﬁcantly
over time. The medication data did not improve the
predictive ability of the index, despite increasing comor-
bidity prevalence.
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